V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330012508 | 330012874 | 1.68 | null | Neo-adjuvant (N) | 2017-06-09 | 2017-07-13 | Hydroxycarbamide | 2 | N | 330022938 | PEMBROLIZUMAB |
| 330012510 | 330005703 | 1.77 | 72 | Radical (R) | 2019-11-13 | 2019-11-13 | CAP | 01 | N | 330023021 | CHOP |
| 330012511 | 330005709 | 1.68 | 58.7 | Curative (C) | 2013-10-26 | 2013-10-26 | MELPHALAN | 02 | N | 330023091 | PAC-PLAT |
| 330012512 | 330005721 | 1.57 | 82 | Curative (C) | 2018-03-17 | 2018-07-16 | ALL UKALL2003 TRIAL | N | N | 330023242 | CLOFARABINE + CYTARABINE |
| 330012513 | 330009126 | 0 | 35.75 | Curative (C) | null | 2017-11-07 | Cisplatin+Doxorubicin+Etoposide 28d | null | N | 330023274 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330012514 | 330005725 | 1.7 | 75 | Palliative (P) | 2018-12-23 | 2018-12-26 | MYELOMA XI TRIAL | 02 | N | 330023279 | PCV |
| 330012515 | 330005743 | 1.79 | 94 | Curative (C) | 2018-09-30 | 2019-01-04 | CHOP R - 21 days | null | null | 330023355 | TRIPLE INTRATHECAL |
| 330012516 | 330005758 | 1.54 | 11 | Radical (R) | 2017-05-14 | 2017-05-14 | Bendamustine +/- Prednisolone | 2 | N | 330023454 | IVAC |
| 330012517 | 330005768 | 1.67 | 16.4 | Palliative (P) | 2018-07-09 | 2018-07-10 | CLADRIBINE | N | null | 330023548 | CISPLATIN + FLUOROURACIL + RT |
| 330012518 | 330009151 | null | null | Disease modification (D) | 2015-05-26 | 2016-01-23 | Cisplatin + Paclitaxel | Y | N | 330023705 | DOXORUBICIN + GEMCITABINE |
| 330012519 | 330005787 | 0 | 59.4 | Curative (C) | 2017-10-23 | 2018-06-15 | Dox + HD Mtx (post PAM) | null | N | 330023758 | UKALL XII |
| 330012520 | 330005790 | 1.59 | null | Palliative (P) | 2017-03-17 | 2017-04-03 | ALL UKALL2003 TRIAL | N | N | 330023791 | IMATINIB |
| 330012521 | 330005792 | 1.82 | 64.15 | Palliative (P) | 2015-02-05 | 2015-05-31 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | null | 330023816 | AML18 TRIAL |
| 330012522 | 330005803 | 1.23 | 61.5 | Neo-adjuvant (N) | 2016-07-22 | 2016-07-25 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | null | 330023868 | UKALL2014 |
| 330012523 | 330005808 | 1.71 | 53.2 | Palliative (P) | 2018-02-25 | 2018-02-28 | Dactinomycin + Vincristine | 2 | N | 330023886 | DOXORUBICIN + METHOTREXATE |
| 330012524 | 330005815 | 1.64 | null | Curative (C) | 2015-07-07 | 2015-07-07 | Doxorubicin + Ifosfamide | 02 | N | 330023933 | EMA/CO |
| 330012525 | 330005820 | null | 76 | Palliative (P) | 2016-05-23 | 2016-06-04 | UKALL14- Intens/CNS Proph | 02 | N | 330023962 | THALIDOMIDE |
| 330012526 | 330005825 | 1.38 | 60.8 | Curative (C) | 2017-06-05 | 2017-06-12 | RUXOLITINIB | N | N | 330024003 | CYTARABINE IT + METHOTREXATE |
| 330012527 | 330005833 | 0 | 82 | Neo-adjuvant (N) | 2018-07-04 | 2018-07-04 | Cyclophosphamide + Vincristine | N | N | 330024076 | CLOFARABINE + CYTARABINE |
| 330012528 | 330005835 | 0 | 62.3 | Palliative (P) | 2014-11-14 | 2014-12-29 | UKALL14- Ph 2 Induction | N | N | 330024112 | MITOTANE |
| 330012529 | 330009180 | 1.69 | 8.5 | Adjuvant (A) | 2017-09-01 | 2018-03-22 | EMA | N | N | 330024126 | VIDE |
| 330012530 | 330005845 | 0 | 87.75 | Palliative (P) | 2017-07-13 | 2017-07-13 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 2 | N | 330024179 | VINCRISTINE |
| 330012531 | 330005848 | 1.57 | 55 | Palliative (P) | 2016-05-01 | 2016-05-03 | FLAG | 02 | N | 330024190 | CAPECITABINE + RT |
| 330012532 | 330005849 | 1.87 | 58 | Curative (C) | 2015-01-19 | 2015-01-19 | POMALIDOMIDE | N | null | 330024195 | CYCLOPHOSPHAMIDE |
| 330012533 | 330005850 | null | 58 | Palliative (P) | null | 2018-11-28 | IPO | null | N | 330024210 | BLINATUMOMAB |
| 330012534 | 330005855 | 1.53 | 60.05 | null | 2017-10-23 | 2017-10-23 | Fludarabine + Melphalan RIC Allo | N | N | 330024241 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330012535 | 330005856 | 1.62 | 58 | Curative (C) | 2017-05-12 | 2017-05-12 | EP/EMA | N | N | 330024258 | DHAP |
| 330012536 | 330009194 | 1.72 | 56.35 | Palliative (P) | 2014-10-25 | 2014-10-25 | Capecitabine + Streptozocin | Y | null | 330024264 | FLUOROURACIL + MITOMYCIN + RT |
| 330012537 | 330005864 | 1.71 | 92.2 | Curative (C) | 2018-07-21 | 2019-04-24 | Sunitinib | N | N | 330024281 | CYTARABINE + IDARUBICIN |
| 330012538 | 330005879 | 1.69 | 81.099 | Palliative (P) | 2016-05-23 | 2016-07-10 | CYCLOPHOSPHAMIDE | N | N | 330024378 | IPM |
| 330012539 | 330005883 | 1.74 | 71.6 | Palliative (P) | 2017-01-21 | 2017-01-31 | IFOSFAMIDE + VINCRISTINE | 02 | N | 330024385 | CISPLATIN + PEMETREXED |
| 330012540 | 330005890 | null | 69 | Curative (C) | null | 2015-08-10 | VIDE | null | N | 330024412 | CVP R |
| 330012542 | 330005902 | null | 111.8 | Palliative (P) | null | 2016-08-11 | MA (Cytarabine 3g/m2) | N | N | 330024492 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 330012543 | 330005908 | 1.86 | null | Palliative (P) | 2015-12-02 | 2015-12-02 | CISPLATIN + GEMCITABINE | N | N | 330024539 | KESTREL TRIAL |
| 330012544 | 330011008 | null | 49.4 | Palliative (P) | 2014-11-19 | 2014-11-19 | Carboplatin + Docetaxel | N | null | 330024541 | CISPLATIN + GEMCITABINE |
| 330012545 | 330005915 | 0 | 57.9 | Palliative (P) | null | 2015-12-18 | CYCLOPHOSPHAMIDE | Y | null | 330024564 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330012546 | 330005920 | 1.67 | 109.2 | Palliative (P) | 2014-02-07 | 2014-02-07 | EMA | N | N | 330024607 | NILOTINIB |
| 330012547 | 330005921 | 1.82 | 17.3 | Palliative (P) | 2014-12-29 | 2014-12-29 | Mitotane 3 - 3.5g | N | null | 330024608 | CHLORAMBUCIL + RITUXIMAB |
| 330012548 | 330005931 | 1.61 | 102.2 | Curative (C) | null | 2016-03-06 | CAPECITABINE + OXALIPLATIN | N | null | 330024744 | OFATUMUMAB |
| 330012549 | 330012890 | 1.71 | 63.3 | Palliative (P) | 2017-12-30 | 2018-01-02 | VINCRISTINE | 2 | N | 330024755 | PEMBROLIZUMAB |
| 330012550 | 330005933 | 1.78 | 106 | Palliative (P) | 2014-10-09 | 2014-11-06 | EDP + MITOTANE | N | N | 330024769 | UKALL60+ |
| 330012551 | 330005941 | 1.67 | 72.2 | Neo-adjuvant (N) | 2017-11-27 | 2018-05-27 | Doxorubicin + Methotrexate | N | N | 330024829 | DHAP |
| 330012552 | 330005945 | 1.7 | 0 | Disease modification (D) | null | 2014-02-12 | Ifosfamide | N | N | 330024851 | VIDE |
| 330012553 | 330011024 | 1.85 | null | null | 2015-03-29 | 2015-03-28 | Cisplatin+Doxorubicin+Etoposide 28d | 02 | N | 330024869 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 330012555 | 330005957 | null | 96 | Curative (C) | 2016-02-08 | 2016-02-18 | CNS LGG 2004 03 vinc weekly+ carbo | 2 | null | 330024888 | ABVD |
| 330012556 | 330005972 | 1.61 | 13.7 | Palliative (P) | 2018-02-01 | 2018-10-24 | Ixazomib + Lenalidomide | 02 | null | 330025024 | EP/EMA |
| 330012557 | 330011033 | 1.8 | null | Palliative (P) | 2015-10-14 | 2015-10-18 | Hydroxycarbamide | Y | N | 330025032 | CARBOPLATIN + CETUXIMAB + FU |
| 330012558 | 330005978 | 1.71 | 17.6 | Curative (C) | 2017-08-26 | 2018-02-28 | FCR | 02 | N | 330025041 | TOPOTECAN |
| 330012559 | 330005980 | 1.72 | 54.3 | Palliative (P) | 2019-09-04 | 2019-09-04 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330025052 | TOPOTECAN |
| 330012560 | 330005984 | 0 | 72.8 | Disease modification (D) | 2017-02-26 | 2017-05-20 | Cladribine (subcut) 5 days | N | N | 330000343 | CYCLOPHOSPHAMIDE |